Nicole Germino
Stock Analyst at Truist Securities
(3.61)
# 796
Out of 4,944 analysts
24
Total ratings
61.9%
Success rate
25.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $18 → $14 | $8.52 | +64.42% | 3 | May 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $3.90 | +105.13% | 3 | May 14, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $122.44 | -11.79% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.53 | +851.66% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $24.42 | -1.72% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $10.76 | - | 2 | Sep 3, 2021 |
Y-mAbs Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $8.52
Upside: +64.42%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.90
Upside: +105.13%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $122.44
Upside: -11.79%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.53
Upside: +851.66%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $24.42
Upside: -1.72%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.76
Upside: -